1. Introduction {#sec1-ijerph-15-01905}
===============

Infection with hepatitis B virus (HBV) is a major public health problem that is associated with high morbidity, high mortality, and high treatment-related costs. Approximately one-third of the global population has serological markers of HBV infection, and more than 240 million people suffer from chronic hepatitis B \[[@B1-ijerph-15-01905]\]. About 800,000 people die each year from complications related to HBV infection, such as cirrhosis and liver cancer \[[@B2-ijerph-15-01905]\]. HBV can be transmitted through percutaneous or mucosal exposure to infected blood or other body fluids \[[@B3-ijerph-15-01905]\]. It can be transmitted through sexual contact, both heterosexual and in men who have sex with men; persons with multiple sexual partners; from mother to child during pregnancy or at birth; among intravenous drug users (IDU); or in healthcare settings where needles are reused \[[@B4-ijerph-15-01905]\]. The prevalence of HBV infection is highest among adults aged 19--49 years in sub-Saharan Africa and East Asia (\>5%). In post-soviet countries and the Middle East, the prevalence of HBV infection varies between 2% and 4%, while in North America and Western Europe the prevalence of HBV infection is below 2% \[[@B5-ijerph-15-01905]\].

In Russia, the history of acute HBV infection in the post-Soviet era can be divided into two periods. The first period was characterized by a substantial increase in the incidence of HBV infection from 22.3 per 100,000 in 1993 to 43.8 per 100,000 in 1999. Since 2000, the incidence of acute HBV infection began to decrease due to the introduction of HBV vaccination, which was first implemented in the Russian Federation in 1990, but it was only administered to high-risk groups in a few regions \[[@B6-ijerph-15-01905]\]. Vaccination of newborns was included in the National Immunization Program in 1997, and vaccination of 13-year-olds in 2001. Despite these measures, the incidence of acute HBV infection in Russia remained high (10.0 per 100,000 in 2004). So, in 2007, the vaccination of the adult population was implemented as a part of the national project "Health" \[[@B7-ijerph-15-01905]\]. Since then, more than 70 million people, approximately 50% of the total population, have been vaccinated, and the incidence of acute HBV infection decreased to 1.1 per 100,000 in 2015. Registration of chronic HBV infection was initiated in 1999; in 2001 the incidence of chronic HBV infection was 16.0 per 100,000 and by 2015, this number had decreased to 10.8 per 100,000 \[[@B8-ijerph-15-01905]\]. According to official statistics, the incidence of both acute and chronic forms of HBV infection in the country is the highest in the age group 20--39 years \[[@B8-ijerph-15-01905]\].

In May 2016, the World Health Organization (WHO) formulated the first Global Health Sector Strategy on Viral Hepatitis, with the stated aim to eliminate these infections. Ten core indicators were proposed to control the spread of these infections, such as prevalence of chronic HBV infection, the number of people living with HBV infection, and coverage of a third dose of HBV vaccine among infants \[[@B9-ijerph-15-01905]\]. This strategy has two targets that are to be achieved by 2030: reduction of the incidence of chronic HBV infection by 90% and reduction of mortality from HBV infection by 65%. The WHO Regional Office for Europe and the European Centre for Disease Prevention and Control assessed the availability of data for each of the core indicators and concluded that they are insufficient to assess the epidemiological burden in many countries in the European region. Therefore they recommended seroprevalence surveys to monitor the prevalence of viral hepatitis, including undiagnosed infections \[[@B10-ijerph-15-01905]\].

The data on serological markers of HBV infection and associated factors in Russia are scarce; we identified only one study in the international peer-reviewed literature \[[@B11-ijerph-15-01905]\]. However, the sample in that study consisted of blood donors and patients from outpatient clinics, with questionable external validity for the general population. The Arkhangelsk Region is situated in Northwest Russia and has an incidence of chronic HBV infection that is similar to the average incidence in Russia as a whole \[[@B12-ijerph-15-01905]\].

To support preventive efforts against HBV, the aim of our study was to assess the prevalence of serological markers of HBV infection, associated factors, and vaccination status among young adults in Arkhangelsk City, Northwest Russia.

2. Materials and Methods {#sec2-ijerph-15-01905}
========================

2.1. Study Population and Study Design {#sec2dot1-ijerph-15-01905}
--------------------------------------

This population-based cross-sectional study was a part of a large Russian-Norwegian project \[[@B13-ijerph-15-01905]\]. The study was carried out in Arkhangelsk City, which has a population of about 350,000. Census data were not available for research purposes, thus the study sample was drawn from the general population using a quota sampling method \[[@B14-ijerph-15-01905]\]. The Agency on Social Research in Arkhangelsk has a database of all cellphone numbers in the city, as well as population-based group-level census data on sex and age distribution ("quotas") in the eight districts of Arkhangelsk City. Using this information, they phoned eligible persons aged 18--39 years and informed them about the aims of the study using a script provided by the study team. Those who agreed to participate presented themselves at the University Clinic of the Northern State Medical University (NSMU) of Arkhangelsk to complete a self-administered questionnaire and provide a blood sample. The enrollment procedure was described previously in detail \[[@B15-ijerph-15-01905]\]. Data collection lasted from the end of September 2010 until June 2011. Altogether, 4872 respondents were contacted to fulfil the "quotas" according to gender and age group. Of them, 3973 agreed to participate; however, the study team ended enrollment after 1265 participants, since this sample size was sufficient according to power calculations. Twenty-two participants had missing blood test results and were excluded from the analyses, resulting in a study sample of 1243 participants.

2.2. Description of the Variables {#sec2dot2-ijerph-15-01905}
---------------------------------

The questionnaire collected information on sociodemographic and socioeconomic factors, sexual and preventive behavior, alcohol use, history of sexually transmitted infections (STIs) other than HIV, and history of HIV infection. Participants reported their family income on a scale of 1 to 10, based on how they thought their income compared to the average income in Arkhangelsk City. We then categorized these responses as low (1--4), medium (5--7), and high (8--10) income. The description of most variables can be found elsewhere \[[@B15-ijerph-15-01905]\].

Self-reported HBV vaccination status was divided into "finished vaccination" (three doses of vaccine), "unfinished vaccination" (one or two doses of vaccine), "unvaccinated" (no dose) and "unknown vaccination status". Previous blood transfusions, surgery, and ever being a blood donor were collapsed into one variable and divided into the categories: "no medical procedure", "one of these medical procedures", "two of these medical procedures", and "all three of these medical procedures". Having tattoos was dichotomized into "yes" and "no". Respondents were asked whether they knew anyone with HBV infection, and responses were divided into "no", "yes", and "don't know".

2.3. Serological Testing {#sec2dot3-ijerph-15-01905}
------------------------

Specimens were sent daily to the research laboratory of the NSMU, where they were centrifuged and frozen at −20 °C. Each month, collected serum specimens were transported to the laboratory of the Regional STI Clinic in Arkhangelsk City, where they were tested for HBV Antigen (HBsAg), HBV core antibodies (anti-HBc), HBV surface antibodies (anti-HBs) and Hepatitis C IgG+IgM antibodies, using an enzyme-linked immunosorbent assay.

Blood samples were also tested for herpes simplex virus type 2 by an enzyme-linked immunosorbent assay for IgG antibodies against the specific HSV-2 glycoprotein g2 \[[@B15-ijerph-15-01905]\]. Main results on the hepatitis C testing are reported elsewhere. All assays were performed according to the manufacturer's instructions. All reagents were manufactured by Vector-Best Company (Novosibirsk, Russia). For the logistic regression analysis participants negative for all serological markers were considered unvaccinated and never-infected, coded as 0. Participants positive for anti-HBs only were considered vaccinated, coded as 0. All other combinations of positivity for serological markers indicated current or previous HBV infection, and were coded as 1 ([Table 1](#ijerph-15-01905-t001){ref-type="table"}).

2.4. Statistical Analyses {#sec2dot4-ijerph-15-01905}
-------------------------

A sample size of 1042 was required to detect odds ratios (ORs) of two or greater in multiple logistic regression analysis with up to seven independent variables for the prevalence of the outcome of 5% or higher with a 95% confidence level. Therefore, we aimed to recruit 1200 subjects, taking into account potential drop-outs and missing data. Categorical variables were analyzed using Pearson's chi-squared tests. Crude and adjusted logistic regression analyses were conducted to assess the association between positivity for serological markers of HBV infection and potential related factors. All variables that were significantly associated with positivity for serological markers of HBV or had a *p*-value \< 0.15 in crude regression analyses were included in the multivariable model, which was used to estimate adjusted ORs and 95% confidence intervals (CIs). All analyses were performed using Statistical Package for Social Sciences version 20 (SPSS Inc., Chicago, IL, USA). Like other authors, we didn't exclude participants who were positive for anti-HBs only (considered as vaccinated) from analyses of risk factors \[[@B16-ijerph-15-01905],[@B17-ijerph-15-01905],[@B18-ijerph-15-01905]\]. There were two reasons for that. Mass vaccination of the adult population started in 2007, 3 years before our study period. Thus, vaccinated persons were protected only a few years prior to their participation in the study. Furthermore, there was no screening for HBV infection before the HBV vaccination program took effect.

2.5. Ethical Approval {#sec2dot5-ijerph-15-01905}
---------------------

The study was conducted in accordance with the Helsinki Declaration and approved by the Ethical Committee at Northern State Medical University in Arkhangelsk on 15 March 2010 (No. 04/03). The participants were given an invitation letter with information about study aims and procedures, and participants were contacted by telephone if they wanted to know their test results. All participants signed a written informed consent form. Since this was not a clinical, but solely a seroepidemilogical study, participants were also asked to provide an e-mail address or telephone number by which they could be contacted and informed in case tests revealed former or present HBV infection. After learning their laboratory results, 42 participants were referred to a specialist in infectious diseases, free of charge.

3. Results {#sec3-ijerph-15-01905}
==========

The study population consisted of 1243 participants, 543 men and 700 women (43.7% and 56.3%, respectively). Most participants had higher or incomplete higher education (58.9%) and 72.0% belonged to the medium income group ([Table 2](#ijerph-15-01905-t002){ref-type="table"}).

The prevalence of serological markers of HBV infection in the full sample was 10.9%, the prevalence among men was 11.8% and among women 10.2% ([Table 1](#ijerph-15-01905-t001){ref-type="table"}). Among our study sample, 46.4% of men and 38.9% of women were negative for all serological markers, 46.9% were positive for anti-HBs only, indicating that they were vaccinated, 1.2% were positive for HBsAg, and 10.7% were positive for anti-HBc ([Table 1](#ijerph-15-01905-t001){ref-type="table"}). The characteristics of the participants positive for HBs Ag are presented in [Table 3](#ijerph-15-01905-t003){ref-type="table"}. Three of the 15 HBAg positive cases had a co-infection with hepatitis C.

In crude logistic regression analyses, positivity for serological markers of HBV infection was positively associated with older age, low income, ever smoking, self-reported STI (other than HIV), reporting ≥2 partners in the last 6 months, and absence of self-reported HBV vaccination. Higher education was negatively associated with positivity for serological markers of HBV infection, indicating a protective effect ([Table 2](#ijerph-15-01905-t002){ref-type="table"} and [Table 4](#ijerph-15-01905-t004){ref-type="table"}).

In addition, in crude logistic analyses, several well-known behavioral risk factors were positively associated with positivity for serological markers of HBV infection, although these associations were not significant, i.e., intravenous drug use and sex with intravenous drug users; early age at sexual debut; sex with a partner of the same gender; not using condoms; two or more previous medical procedures; having tattoos; knowing someone with HBV infection; and not considering HBV vaccination necessary. The prevalence of serological markers of HBV infection in these groups was higher compared to their counterparts without these factors. Among the 543 men in our study, 18 (3.3%) reported having sex with a partner of the same gender. In this group, the prevalence of serological markers of HBV infection was 16.7% (95% CI 5.84--39.23), and the crude OR for being positive for serological markers of HBV infection was 1.5 (95% CI 0.42--5.36). The prevalence among men having sex with men was the highest prevalence found in this study, together with those who reported three medical procedures. This group counted also only 18 persons, 16.7% were positive for serological markers for HBV infection, and crude OR was 1.64 (95% CI 0.46--5.82) The prevalence of serological markers of HBV infection among men who had never had sex with men was 11.7% (95% CI 9.23--14.76). Among women, ever having sex with a partner of the same gender was not associated with positivity for serological marker of HBV infection in crude log regression analyses (OR = 1.02; 95% CI 0.30--3.48).

In our study sample, 42.5% of participants reported that they had received at least one dose of HBV vaccine, and 30.6% did not know whether or not they were vaccinated; however, in the latter group, 43.2% had isolated anti-HBs antibodies. Serological markers of HBV infection were found among 8.4% of men and 7.9% of women who reported receiving three doses of HBV vaccine ([Table 2](#ijerph-15-01905-t002){ref-type="table"}), and 36% and 26%, respectively, did not know if they were vaccinated against HBV. At the same time, the vast majority of participants (\>90%) agreed or tended to agree that vaccination against HBV was necessary, and serological testing actually showed that 46.9% were vaccinated.

In the multivariable logistic regression analysis, age 30--34 years, absence of self-reported vaccination, and having ≥2 sexual partners in the last 6 months were significantly associated with positivity for serological markers of HBV infection, and self-reported history of STI was borderline significant ([Table 5](#ijerph-15-01905-t005){ref-type="table"}).

4. Discussion {#sec4-ijerph-15-01905}
=============

To our knowledge, our study is the most recent serosurvey on markers of HBV in the general population of Northwest Russia. It was conducted after the initiation of mass HBV vaccination programs in the young adult population, and it combined serological markers of HBV infection and vaccination with data on risk behavior.

4.1. Prevalence of Serological Markers of Hepatitis B Virus Infection and Vaccination {#sec4dot1-ijerph-15-01905}
-------------------------------------------------------------------------------------

Fifteen persons in our study sample (six men and nine women, 1.2% of the study sample) tested positive for HBsAg and could thus infect others. According to World Health Organization classifications, a prevalence of 1.2% is categorized as a low-prevalence population \[[@B3-ijerph-15-01905]\]. Indeed, the prevalence we observed is comparable with that found in the general population of Spain, Italy, and Greece. The same prevalence was found in the Moscow region in 2008 among first-time blood donors and people attending outpatient clinics \[[@B11-ijerph-15-01905],[@B19-ijerph-15-01905]\]. However, such comparisons should be done with caution, because donors do not always represent the general population and may have a lower prevalence of HBsAg \[[@B20-ijerph-15-01905]\]. According to the regional Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing in Arkhangelsk, the prevalence of HBsAg among blood donors in the region in 2010--2015 was less than 0.2% \[[@B21-ijerph-15-01905]\]; however the prevalence of HBsAg is several times higher among young adults in Arkhangelsk City in our study.

In the present study, positivity for anti-HBc and/or HBsAg combined with negativity for HBsAg was considered as "ever being infected" with HBV. The childhood or youth of our participants coincided with the early post-soviet era. During this period, risk factors for HBV increased in the population, such as intravenous drug use and a freer sexual lifestyle \[[@B22-ijerph-15-01905],[@B23-ijerph-15-01905]\]. The situation was aggravated by the absence of HBV vaccination. The prevalence of anti-HBc was 10.7% in our study. This figure is lower than that reported from six regions of Russia in 2008 \[[@B11-ijerph-15-01905]\]. Our results also fit with the incidence rate of acute HBV infection in the Arkhangelsk Region, which has decreased more during last 20 years than in other regions \[[@B11-ijerph-15-01905],[@B24-ijerph-15-01905]\]. The prevalence of anti-HBc among our participants was close to that reported in Poland, where 10.3% of adults were positive for this marker \[[@B25-ijerph-15-01905]\]. Data from Tajikistan showed that 30% of 15--24-year-olds are positive for anti-HBc, compared to 47% of adults aged 20--59 years in China, and 57.4% of adults aged 20--39 years in Nigeria \[[@B16-ijerph-15-01905],[@B26-ijerph-15-01905],[@B27-ijerph-15-01905]\]. Data from other parts of the world demonstrate that the higher the proportion of the vaccinated population, the lower the proportion of HBV-infected individuals: in Poland 55% of the adult population is vaccinated, and in China and Nigeria these values are 23.7% and 7.9%, respectively \[[@B16-ijerph-15-01905],[@B25-ijerph-15-01905],[@B27-ijerph-15-01905]\].

Medical records of our participants were not available for this study, so we asked participants to self-report their vaccination status. Among them, 42.5% reported having at least one dose of HBV vaccine ([Table 3](#ijerph-15-01905-t003){ref-type="table"}), but 46.9% were positive for anti-HBs, only, according to laboratory tests ([Table 1](#ijerph-15-01905-t001){ref-type="table"}). These data correspond pretty well with official statistics, which state that 50% of the adult population in Arkhangelsk was vaccinated by the beginning of 2011 \[[@B28-ijerph-15-01905]\]. The impact of universal vaccination in Russia was assessed by the researchers from Moscow. According to their estimations, 91--95% of cases of acute and chronic HBV infection that would otherwise occur are, in fact, prevented by HBV vaccination \[[@B11-ijerph-15-01905]\]. Interestingly, 30.6% of our participants didn't know whether or not they had been vaccinated against HBV. By comparison, in a Chinese population-based survey only 9.2% of adults didn't know their vaccination status. These data demonstrate another specific feature of Russian society formulated by Russian sociologists: nowadays young adults in Russia have a relatively low level of healthcare seeking and a low level of knowledge about their health \[[@B29-ijerph-15-01905]\]. Among young adults in our study, 42.1% were still susceptible to HBV infection, so the mass vaccination campaign for adults should be continued.

4.2. Factors Associated with Positivity for Serological Markers of Hepatitis B Virus {#sec4dot2-ijerph-15-01905}
------------------------------------------------------------------------------------

The prevalence of serological markers of HBV among participants aged 30--39 years was two times higher than the prevalence in those aged 18--29 years. The same trend was observed for anti-HBc in the Moscow region \[[@B11-ijerph-15-01905]\] and for HBsAg among pregnant women in Bulgaria \[[@B30-ijerph-15-01905]\], but it was not observed in surveys from Nigeria, China, India, and the Lao People's Democratic Republic \[[@B16-ijerph-15-01905],[@B31-ijerph-15-01905],[@B32-ijerph-15-01905],[@B33-ijerph-15-01905]\].

In our study, participants with low education or income level had a higher prevalence of serological markers of HBV infection. These markers were negatively associated with higher education and income variables in crude log regression analyses, indicating a protective effect. In multivariable analyses these associations were still negative, but they were not significant. Other studies have also found a higher prevalence of markers of HBV infection among people with the lowest level of education \[[@B16-ijerph-15-01905],[@B18-ijerph-15-01905],[@B34-ijerph-15-01905]\] or income \[[@B32-ijerph-15-01905]\].

HBV is highly contagious and easily transmitted sexually \[[@B5-ijerph-15-01905]\]. In our study participants with a history of STI and multiple sexual partners (≥2 in the past 6 months) had a higher risk of HBV infection. For the last 7 years sexual transmission of HBV infection has also been one of the most common routes of transmission reported in the Arkhangelsk Region \[[@B21-ijerph-15-01905]\]. Multiple sexual partners and a history of STI have been also associated with HBV infection in previous studies \[[@B35-ijerph-15-01905],[@B36-ijerph-15-01905],[@B37-ijerph-15-01905]\]. Men who have sex with men are considered a high-risk group \[[@B4-ijerph-15-01905]\]. In our study, positivity for serological markers of HBV was positively associated with belonging to this group, but this association was not significant in crude regression analyses. This can probably be explained by the small number of individuals in this risk group. Indeed, the prevalence of markers of HBV infection among men who have sex with men in our study was close to that observed in the USA (17% versus 19%) \[[@B38-ijerph-15-01905]\].

Intravenous drug use is an important risk factor for HBV infection, which is also the case in Arkhangelsk region \[[@B4-ijerph-15-01905],[@B21-ijerph-15-01905]\]. In crude logistic regression injecting drug use was associated with seropositivity of HBV markers ([Table 4](#ijerph-15-01905-t004){ref-type="table"}). However this association was not significant. This might be due to lack of power and insufficient number of participants recognized themselves as ever being drug users.

4.3. Strengths and Weaknesses of the Study {#sec4dot3-ijerph-15-01905}
------------------------------------------

Due to the cross-sectional design, a temporal relationship between risk behavior and positivity for markers of HBV could not be established. Moreover, as we investigated the young adult population, so we cannot generalize our results to neither the whole Russian population nor the entire adult population of Arkhangelsk City. We asked if the participants knew any with HBV infection, but we did not ask if family members had present or former HBV infection. Thus, we did not attempt to assess any HBV transmission from mother to child that might have happened nearly 2--4 decades ago. This may be considered as limitation of the study. In addition, the study questionnaire contained sensitive questions, which may have caused social desirability bias due to underreporting of high-risk behavior \[[@B39-ijerph-15-01905]\]. Blood sampling can be seen as unpleasant by some, and may have been a deterrent to study participation \[[@B40-ijerph-15-01905]\]. Our sampling method cannot rule out selection bias, for instance through recruitment via cellphone owners; therefore generalization of our study results should be avoided. Participants received compensation high enough to pay for a taxi to and from the clinic, and this likely secured participation among people with low income.

The main strength of our study is its population-based design, including both sexes. We chose to study young adults, as this group has the highest risk of getting the infection \[[@B8-ijerph-15-01905]\]. Moreover, the most frequent routes of HBV transmission in the region are sexual transmission, intravenous drug use, beauty treatments (e.g., tattoos, pedicures, etc.), and from mother to child, and thus relate to this age group \[[@B21-ijerph-15-01905]\]. Another benefit of our study is the time period in which we carried out of the investigation---soon after the completion of mass immunization project in the adult population. Most of the vaccinated adults in Russia were immunized in 2007--2009. So, in 2010--2011 we had a unique chance to investigate herd immunity and the association of risk factors for HBV markers in the general population. Most of our participants were vaccinated only 1--2 years prior to the study; before that they were not protected and were susceptible to HBV infection. According to the official data, the percentage of vaccinated adults aged 18--35 years was more than 80% in 2016 \[[@B41-ijerph-15-01905]\]. So, now the study of the associations between risk factors and positivity for HBV markers would be difficult. Another strength of our study is it was designed as a "second-generation HIV/STI survey", which combines biological indicators with data on risk behavior to provide information for HIV/STI preventive efforts \[[@B42-ijerph-15-01905]\] and provide useful data for monitoring the situation according to Global Health Sector Strategy on viral hepatitis \[[@B9-ijerph-15-01905]\].

5. Conclusions {#sec5-ijerph-15-01905}
==============

The prevalence of HBV markers in our study was close to that observed in Southern and Eastern European countries. Although half of our participants were protected against HBV thanks to mass adult vaccination, more than four in ten were still susceptible to HBV infection and there were individuals with active HBV infection of whom most did not know that they were infected. Therefore the work of HBV prevention should be continued at all levels, including federal financial support of free-of-charge HBV vaccination as part of the National Project "Health", promotion of the HBV vaccination campaign at the regional level, and routine work at the local level, i.e., by recommending that physicians test for and treat HBV infections and encourage their patients to be vaccinated during regular check-ups and before operations; by using mass media and social networks to spread information about HBV infection; and by encouraging people to be vaccinated to protect themselves, their partners, and their children.
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###### 

Prevalence of serological markers of HBV infection and HBV vaccination status in a population-based study of adults aged 18--39 years, Arkhangelsk City, Russia, 2010--2011.

  Serological Markers of HBV Infection ^a^/Vaccination   Interpretation of Lab Results   Males      Females                                 Total                               
  ------------------------------------------------------ ------------------------------- ---------- --------------------------------------- ------- ------ ------ ------ ------ ------
  Negative                                               Negative                        Negative   Uninfected, HBV infection susceptible   252     46.4   272    38.9   524    42.1
  Negative                                               Negative                        Positive   Vaccinated                              227     41.8   356    50.9   583    46.9
  Negative                                               Positive                        Positive   Current or previous HBV infection       31      5.7    53     7.6    84     6.7
  Negative                                               Positive                        Negative   27                                      5.0     10     1.4    37     3.0    
  Positive                                               Positive                        Negative   5                                       0.9     1      0.15   6      0.5    
  Positive                                               Positive                        Positive   1                                       0.2     5      0.7    6      0.5    
  Positive                                               Negative                        Negative   0                                       0.0     2      0.3    2      0.2    
  Positive                                               Negative                        Positive   0                                       0.0     1      0.15   1      0.1    
  Total                                                                                                                                     543     100    700    100    1243   100

^a^ Serological markers of HBV infection: HBsAg and/or anti-HBc; Abbreviations: HBV: hepatitis B virus; HBsAg: HBV surface Antigen; anti-HBc: HBV core antibodies; anti-HBs: HBV surface antibodies.
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###### 

Prevalence of serological markers of HBV infection and crude associations between positivity for serological markers of HBV infection and sociodemographic factors in a population-based study of 1243 adults aged 18--39 years, Arkhangelsk City, Russia, 2010--2011.

  -------------------------------------------------------------------------------------------------------------------------
  Variables                                         *n*    \%     Prevalence (%)\                  Crude OR   95% CI ^b^
                                                                  Serological Markers of HBV ^a^              
  ------------------------------------------------- ------ ------ -------------------------------- ---------- -------------
  **Age**                                                                                                     

  18--24 years                                      497    40.0   7.0                              referent   

  25--29 years                                      296    23.8   9.8                              1.43       0.86--2.40

  30--34 years                                      278    22.4   16.5                             2.62       1.64--4.18

  35--39 years                                      172    13.8   15.1                             2.35       1.37--4.04

  **Sex**                                                                                                     

  Men                                               543    43.7   11.8                             referent   

  Women                                             700    56.3   10.3                             0.86       0.60--1.23

  **Education**                                                                                               

  Low (secondary education, 10--11 years or less)   209    16.8   15.8                             referent   

  Average (secondary vocational education)          302    24.3   9.9                              0.59       0.35--0.999

  High (incomplete higher and higher education)     732    58.9   10.0                             0.59       0.38--0.92

  **Marital status**                                                                                          

  Single                                            571    45.9   8.2                              referent   

  Widowed, divorced                                 86     6.9    14.0                             1.81       0.92--3.57

  Co-habitation                                     213    17.1   14.6                             1.90       1.17--3.08

  Married                                           373    30.0   12.3                             1.57       1.02--2.41

  **Income ^c^**                                                                                              

  Low income 1--4                                   207    16.7   15.5                             referent   

  Medium income 5--7                                895    72.0   10.1                             0.61       0.40--0.95

  High income 8--10                                 141    11.3   9.9                              0.60       0.31--1.18

  **Total**                                         1243   100    10.9                                        
  -------------------------------------------------------------------------------------------------------------------------

^a^ serological markers of HBV infection: HBsAg and/or anti-HBc; ^b^ significant association in bold; ^c^ subjective estimation by comparing own family income with family income on average in Arkhangelsk; Abbreviations: HBV: hepatitis B virus; OR: odds ratio; CI: confidence interval; HBsAg: HBV surface Antigen; anti-HBc: HBV core antibodies.
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###### 

The characteristic of the participants positive on HBs Ag (*N* = 15) in a population-based study of adults aged 18--39 years, Arkhangelsk City, Russia, 2010--2011.

  Variables                                                  *N* (%)
  ---------------------------------------------------------- ------------
  **Gender**                                                 
  Male                                                       6 (40%)
  Female                                                     9 (60%)
  **Median age**                                             30
  **Ever being diagnosed with hepatitis B**                  
  No                                                         13 (86.7%)
  Yes                                                        2 (13.3%)
  **Injecting drug use**                                     
  No                                                         14 (93.3%)
  Yes                                                        0 (0%)
  Do not want to answer                                      1 (6.7%)
  **Co-infection with hepatitis C virus \***                 
  No                                                         12 (80%)
  Yes                                                        3 (20%)
  **Knowing someone with hepatitis B**                       
  No                                                         8 (53.3%)
  Yes                                                        4 (26.7%)
  Do not know                                                3 (20.0%)
  **Ever being a blood donor**                               
  No                                                         11 (73.3%)
  Yes                                                        4 (26.7%)
  **Previous blood transfusions**                            
  No                                                         15 (100%)
  **Previous surgery**                                       
  No                                                         12 (80%)
  Yes                                                        3 (20%)
  **Have you ever had sex with an intravenous drug user?**   
  No                                                         13 (86.7%)
  Yes                                                        1 (6.7%)
  Do not know                                                1 (6.7%)
  **Having tatoos**                                          
  No                                                         13 (86.7)
  Yes                                                        2 (13.3)

\* positive on IgM + G.
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###### 

Prevalence of serological markers of HBV infection and crude associations between positivity for serological markers of HBV infection and behavioral factors in a population-based study of 1243 adults aged 18--39 years, Arkhangelsk City, Russia, 2010--2011.

  -------------------------------------------------------------------------------------------------------------------------------------
  Variables                                                      *N*    \%     Prevalence (%)\                  Crude OR   95% CI ^b^
                                                                               Serological Markers of HBV ^a^              
  -------------------------------------------------------------- ------ ------ -------------------------------- ---------- ------------
  Smoking                                                                                                                  

  Never smoked                                                   491    39.5   8.6                              referent   

  Ever smoked                                                    752    60.5   12.5                             1.53       1.04--2.24

  Binge drinking ^c^                                                                                                       

  Never                                                          242    19.5   9.1                              referent   

  Ever                                                           1001   80.5   11.4                             1.29       0.80--2.08

  Self-reported STI (without HSV-2 or HIV)                                                                                 

  Never and don't know                                           996    80.1   9.5                              referent   

  Yes                                                            247    19.9   16.6                             1.89       1.27--2.81

  HSV-2 lab test                                                                                                           

  Negative                                                       1008   81.2   10.3                             referent   

  Positive                                                       234    18.8   13.7                             1.38       0.90--2.11

  N of sexual partners in last 6 months                                                                                    

  0 and 1                                                        941    75.7   9.9                              referent   

  ≥2                                                             302    24.3   14.2                             1.51       1.03--2.23

  Lifetime N of sexual partners                                                                                            

  0 and 1                                                        134    10.8   6.7                              referent   

  2--5                                                           424    34.1   9.9                              1.53       0.72--3.23

  6 and more                                                     685    55.1   12.4                             1.97       0.96--4.02

  Use of condom during last sexual encounter                                                                               

  Yes ^d^                                                        339    27.3   8.6                              referent   

  No and don't remember ^e^                                      904    72.7   11.8                             1.44       0.93--2.21

  Use of condom with a steady partner                                                                                      

  Always ^d^                                                     270    21.7   8.9                              referent   

  Rarely and sometimes                                           563    45.3   10.7                             1.22       0.74--2.01

  Never                                                          410    33.0   12.7                             1.49       0.89--2.48

  Use of condom with casual partner                                                                                        

  Always or never had casual partners                            1112   89.5   11.0                             referent   

  Sometimes, rarely, never                                       131    10.5   10.7                             0.97       0.54--1.74

  Using of injected drugs                                                                                                  

  Never                                                          1209   97.3   10.8                             referent   

  Ever                                                           34     2.7    14.7                             1.42       0.54--3.73

  Have you ever had sex with an intravenous drug user?                                                                     

  No                                                             1094   88.0   10.3                             referent   

  Yes                                                            45     3.6    15.6                             1.60       0.70--3.67

  Don't know                                                     104    8.4    15.4                             1.58       0.90--2.78

  Age at sexual debut                                                                                                      

  ≥18 ^d^                                                        517    41.6   9.5                              referent   

  ≤17                                                            726    58.4   12.0                             1.30       0.90--1.88

  Ever having sex with a partner of the same gender                                                                        

  No                                                             1197   96.3   10.9                             referent   

  Yes                                                            46     3.7    13.0                             1.23       0.51--2.96

  Previous blood transfusions, surgery, ever being blood donor                                                             

  No medical procedures                                          551    44.3   10.9                             referent   

  One of these medical procedures                                546    43.9   10.3                             0.94       0.64--1.38

  Two of these medical procedures                                128    10.3   13.3                             1.25       0.70--2.23

  Three of these medical procedures                              18     1.4    16.7                             1.64       0.46--5.82

  Having tattoos                                                                                                           

  No                                                             1071   86.2   10.6                             referent   

  Yes                                                            172    13.8   13.4                             1.31       0.81--2.12

  Knowing someone with HBV infection                                                                                       

  No                                                             865    69.6   10.2                             referent   

  Yes                                                            184    14.8   14.7                             1.52       0.96--2.42

  Don't know                                                     194    15.6   10.8                             1.07       0.65--1.77

  Vaccination against HBV                                                                                                  

  Yes, three doses                                               384    30.9   8.1                              referent   

  Yes, one or two doses                                          144    11.6   10.4                             1.32       0.69--2.53

  Don't know                                                     380    30.6   11.1                             1.42       0.87--2.30

  No                                                             335    27.0   14.3                             1.90       1.18--3.07

  "Vaccination against HBV is necessary"                                                                                   

  Agree and tend to agree                                        1140   91.7   10.7                             referent   

  Disagree and tend to disagree                                  44     3.5    15.9                             1.58       0.69--3.62

  Don't know                                                     59     4.7    11.9                             1.12       0.50--2.53
  -------------------------------------------------------------------------------------------------------------------------------------

^a^ = serological markers of HBV infection: HBsAg and/or anti-HBc. ^b^ = significant association in bold. ^c^ = drinking 6 or more units in one occasion. ^d^: Includes 18 participants reporting no sexual debut. ^e^: Includes 11 participants who did not remember. Abbreviations: HBV: hepatitis B virus; OR: odds ratio; CI: confidence interval; STI: sexually transmitted infection; *N*: number; herpes simplex virus type 2 (HSV-2), HBsAg: HBV surface Antigen; anti-HBc: HBV core antibodies.
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###### 

Serological markers of HBV infection ^a^ and correlates by multivariable logistic regression analysis in a population-based study of 1243 adults aged 18--39 years, Arkhangelsk City, Russia, 2010--2011.

  Variables                                          Adjusted OR   95% CI ^b^
  -------------------------------------------------- ------------- ----------------
  Age                                                              
  18--24 years                                       Referent      
  25--29 years                                       1.10          0.63--1.94
  30--34 years                                       **1.99**      **1.15--3.43**
  35--39 years                                       1.68          0.89--3.16
  Education                                                        
  Low (secondary education (10--11 years) or less)   Referent      
  Average (secondary vocational education)           0.61          0.35--1.06
  High (incomplete higher and higher education)      0.75          0.46--1.22
  Marital status                                                   
  Single                                             Referent      
  Widowed, divorced                                  1.05          0.50--2.23
  Co-habitation                                      1.73          1.00--2.98
  Married                                            1.32          0.79--2.18
  Income ^c^                                                       
  Low income 1--4                                    Referent      
  Medium income 5--7                                 0.69          0.44--1.09
  High income 8--10                                  0.70          0.35--1.41
  Smoking                                                          
  Never smoked                                       Referent      
  Ever smoked                                        1.25          0.81--1.91
  Vaccination against HBV                                          
  Yes, three doses                                   Referent      
  Yes, one or two doses                              1.36          0.70--2.66
  Don't know                                         1.40          0.84--2.33
  No                                                 **1.68**      **1.02--2.77**
  Self-reported STI (without HSV-2 or HIV)                         
  Never and don't know                               Referent      
  Yes                                                1.53          0.99--2.34
  HSV-2                                                            
  Negative                                           Referent      
  Positive                                           0.95          0.60--1.50
  No. of sexual partners in the last 6 months                      
  0 and 1                                            Referent      
  ≥2                                                 1.61          **1.02--2.54**
  Lifetime no. of sexual partners                                  
  0 and 1                                            Referent      
  2--5                                               1.32          0.61--2.86
  6 and more                                         1.14          0.52--2.49
  Use of condom during last sexual encounter                       
  Yes ^d^                                            Referent      
  No and don't remember ^e^                          1.20          0.67--2.15
  Use of condom with a steady partner                              
  Always ^d^                                         Referent      
  Rarely and sometimes                               0.93          0.49--1.75
  Never                                              0.93          0.46--1.87
  Have you ever had sex with IDU?                                  
  No                                                 Referent      
  Yes                                                1.16          0.48--2.81
  Don't know                                         1.18          0.64--2.19
  Knowing someone with HBV infection                               
  No                                                 Referent      
  Yes                                                1.48          0.91--2.41
  Don't know                                         0.99          0.59--1.68

^a^ Serological markers of HBV infection: HBsAg and/or anti-HBc; ^b^ Significant association in bold; ^c^ Subjective estimation by comparing own family income with family income on average in Arkhangelsk; ^d^ Includes 18 participants reporting no sexual debut; ^e^ Includes 11 participants who did not remember; Abbreviations: HBV: hepatitis B virus; OR: odds ratio; CI: confidence interval; STI: sexually transmitted infection; herpes simplex virus type 2 (HSV-2), HBsAg: HBV surface Antigen; anti-HBc: HBV core antibodies; IDU: intravenous drug user. Significant results were marked in bold.
